Lindsay R Freud, Stephanie Galloway, T Blaine Crowley, Julie Moldenhauer, Ann Swillen, Jeroen Breckpot, Antoni Borrell, Neeta L Vora, Bettina Cuneo, Hilary Hoffman, Lisa Gilbert, Beata Nowakowska, Maciej Geremek, Anna Kutkowska-Kaźmierczak, Joris R Vermeesch, Koen Devriendt, Tiffany Busa, Sabine Sigaudy, Trisha Vigneswaran, John M Simpson, Jeffrey Dungan, Nina Gotteiner, Karl-Philipp Gloning, Maria Cristina Digilio, Marta Unolt, Carolina Putotto, Bruno Marino, Gabriela Repetto, Magdalena Fadic, Sixto Garcia-Minaur, Ana Achón Buil, Mary Ann Thomas, Deborah Fruitman, Taylor Beecroft, Pui Wah Hui, Solveig Oskarsdottir, Rachael Bradshaw, Amanda Criebaum, Mary E Norton, Tiffany Lee, Miwa Geiger, Leslie Dunnington, Jacqueline Isaac, Louise Wilkins-Haug, Lindsey Hunter, Claudia Izzi, Marika Toscano, Tullio Ghi, Julie McGlynn, Francesca Romana Grati, Beverly S Emanuel, Kimberly Gaiser, J William Gaynor, Elizabeth Goldmuntz, Daniel E McGinn, Erica Schindewolf, Oanh Tran, Elaine H Zackai, Qi Yan, Anne Bassett, Ronald Wapner, Donna M McDonald-McGinn
BACKGROUND: 22q11.2 deletion syndrome (22qDS) is the most common microdeletion syndrome and is frequently associated with congenital heart disease (CHD). Prenatal diagnosis of 22qDS is increasingly offered. It is unknown whether there is a clinical benefit to prenatal detection as compared to postnatal diagnosis. OBJECTIVE: To determine differences in perinatal and infant outcomes between patients prenatally or postnatally diagnosed with 22qDS. STUDY DESIGN: Retrospective cohort study across multiple international centers (30 sites, 4 continents) from 2006 to 2019...
September 15, 2023: American Journal of Obstetrics and Gynecology